Takumi Maruhashi

Takumi Maruhashi

Auto-generated profile, based on publicly available information

Takumi Maruhashi

Laboratory of Molecular Immunology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TMTakumi Maruhashi
Takumi Maruhashi
DSDaisuke Sugiura
Daisuke Sugiura
IOIl-Mi Okazaki
Il-Mi Okazaki
TOTaku Okazaki
Taku Okazaki
To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points. Inhibitory coreceptors, including programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against self-tissues and tumor cells. Immune checkpoint inhibitors that block PD-1 and CTLA-4 pathways significantly improved the outcomes of patients with diverse cancer types and have revolutionized cancer treatment. However, response rates to such therapies are rather limited, and immune-related adverse events are also observed in a substantial patient population, leading to the urgent need for novel therapeutics with higher efficacy and lower toxicity. In addition to PD-1 and CTLA-4, a variety of stimulatory and inhibitory coreceptors are involved in the regulation of T cell activation. Such coreceptors are listed as potential drug targets, and the competition to develop novel immunotherapies targeting these coreceptors has been very fierce. Among such coreceptors, lymphocyte activation gene-3 (LAG-3) is expected as the foremost target next to PD-1 in the development of cancer therapy, and multiple clinical trials testing the efficacy of LAG-3-targeted therapy are underway. LAG-3 is a type I transmembrane protein with structural similarities to CD4. Accumulating evidence indicates that LAG-3 is an inhibitory coreceptor and plays pivotal roles in autoimmunity, tumor immunity, and anti-infection immunity. In this review, we summarize the current understanding of LAG-3, ranging from its discovery to clinical application.

10 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
DSDaisuke Sugiura
Daisuke Sugiura
TMTakumi Maruhashi
Takumi Maruhashi
IOIl-Mi Okazaki
Il-Mi Okazaki
KSKenji Shimizu
Kenji Shimizu
TMTakeo K. Maeda
Takeo K. Maeda
TOTaku Okazaki
Taku Okazaki
Sparing T cells from inhibition: Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558

1 April 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TMTakumi Maruhashi
Takumi Maruhashi
Isao KiiIsao Kii
Isao Kii
MSMitsuru Saito
Mitsuru Saito
AKAkira Kudo
Akira Kudo
Intra- and intermolecular covalent cross-linking between collagen fibrils, catalyzed by lysyl oxidase (LOX), determines the mechanical properties of connective tissues; however, mechanisms that regulate the collagen cross-linking according to tissue specificity are not well understood. Here we show that periostin, a secretory protein in the dense connective tissues, promotes the activation of LOX. Previous studies showed that periostin null mice exhibit reduced collagen cross-linking in their femurs, periosteum, infarcted myocardium, and tendons. Presently, we showed that active LOX protein, formed by cleavage of its propeptide by bone morphogenetic protein-1 (BMP-1), was decreased in calvarial osteoblast cells derived from periostin null mice. Overexpression of periostin promoted the proteolytic cleavage of the propeptide, which increased the amount of active LOX protein. The results of co-immunoprecipitation and solid phase binding assays revealed that periostin interacted with BMP-1. Furthermore, this interaction probably resulted in enhanced deposition of BMP-1 on the extracellular matrix, suggesting that this enhanced deposition would lead to cleavage of the propeptide of LOX. Thus, we demonstrated that periostin supported BMP-1-mediated proteolytic activation of LOX on the extracellular matrix, which promoted collagen cross-linking.

22 October 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TMTakumi Maruhashi
Takumi Maruhashi
IOIl-Mi Okazaki
Il-Mi Okazaki
DSDaisuke Sugiura
Daisuke Sugiura
STSuzuka Takahashi
Suzuka Takahashi
TMTakeo K. Maeda
Takeo K. Maeda
TOTaku Okazaki
Taku Okazaki

11 April 2022 in Immunity
Verified
Journal Article
Closed access
TMTakumi Maruhashi
Takumi Maruhashi
DSDaisuke Sugiura
Daisuke Sugiura
IOIl-Mi Okazaki
Il-Mi Okazaki
KSKenji Shimizu
Kenji Shimizu
TMTakeo K. Maeda
Takeo K. Maeda
TOTaku Okazaki
Taku Okazaki

29 March 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RMReina Mizuno
Reina Mizuno
DSDaisuke Sugiura
Daisuke Sugiura
KSKenji Shimizu
Kenji Shimizu
TMTakumi Maruhashi
Takumi Maruhashi
MWMizuki Watada
Mizuki Watada
TOTaku Okazaki
Taku Okazaki
Cancer-immunotherapy targeting programmed cell death 1 (PD-1) activates tumor-specific T cells and provides clinical benefits in various cancers. However, the molecular basis of PD-1 function is still enigmatic. Especially, it is unclear which signaling pathway PD-1 primarily targets. Besides, the capacity of PD-1 to inhibit the T cell receptor (TCR)-dependent activation of T cells in the presence of co-stimulation is also controversial. Here we used co-culture systems of T cells and antigen-presenting cells with targeted deletion and overexpression of co-receptors and ligands and examined the inhibitory potency of PD-1 against T cell activation upon TCR stimulation with CD28 and ICOS co-stimulation. As an unambiguous criterion of T cell activation, we used the acquisition of cytokine production capacity, which represents one of the most important functions of T cells. PD-1 inhibited functional T cell activation upon TCR stimulation in the absence as well as in the presence of CD28 co-stimulation, indicating that PD-1 can directly inhibit TCR signal. Notably, CD28 co-stimulation rather attenuated the efficiency of PD-1 in inhibiting TCR-dependent functional T cell activation. In addition, PD-1 inhibited TCR-dependent functional T cell activation with ICOS co-stimulation as efficiently as that with CD28 co-stimulation. Furthermore, we found that the maintenance of antigen-induced follicular helper T (TFH) cells that required ICOS co-stimulation was persistently restrained by PD-1 in vivo. These findings indicate that PD-1 primarily targets TCR signal in the inhibition of functional T cell activation. Thus, PD-1 functions as the rheostat of T cell activation rather than an inhibitor of a specific stimulatory co-receptor.